Announced Sun, 29 Mar · 17:42 IST

Update under Regulation 30 read with Para A Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

MEDPLUS · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
-0.3%1-day move
₹825.00
prior close
₹820.00
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+0.1+0.5+0.5+0.3-0.3+0.8+0.7+2.4+5.4+5.1+10.9+6.4+6.4-2.0
Up moveDown movePending
AI summary

MedPlus Health Services has informed that its subsidiary, Optival Health Solutions Private Limited, received a 3-day suspension order for the drug license of its store at Parkal Main Road, Telangana. The order was issued by the Assistant Director, Drugs Control Administration, Warangal, under Rule 65 of the Drugs and Cosmetics Act, 1940. The order was received on March 28, 2026. The company has stated the potential revenue loss from this suspension is only Rs 0.60 lacs (approximately ₹60,000), which is negligible compared to MedPlus's overall operations.

Likely market impact

The financial impact is minimal — a potential loss of just Rs 0.60 lacs from a single store for 3 days. This is a routine regulatory action with no material effect on the company's overall business or operations.